SCHEMBL20031366

SCHEMBL20031366

CCC(C)(C)c1cc(C(F)(F)F)ccn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 1/20 0.47
NOS2 P35228 1/20 0.47
ADRB2 P07550 1/20 0.43
ALDH1A1 P00352 1/20 0.40
GAA P10253 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
LOXL2 Q9Y4K0 2/20 0.40
LOX P28300 1/20 0.39
ADRB1 P08588 1/20 0.37
AR P10275 1/20 0.36
DDR1 Q08345 1/20 0.35
MAPK1 P28482 1/20 0.35
NPSR1 Q6W5P4 1/20 0.34
RORC P51449 1/20 0.34
CETP P11597 4/20 0.33
PNMT P11086 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
PSEN1 P49768 1/20 0.33
PSEN2 P49810 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18745826 0.87 LOXL2 (0.49) NOS3NOS2ADRB2ALDH1A1GAA
SCHEMBL20122650 0.86 LOXL2 (0.34) NOS3NOS2ADRB2ALDH1A1GAA
SCHEMBL18532052 0.85 LMNA (0.35) ALDH1A1L3MBTL1MAPK1NPSR1CYP2D6
SCHEMBL2609325 0.81 NOS3 (0.53) NOS3NOS2ADRB2ALDH1A1GAA
SCHEMBL18699091 0.81 MAPK1 (0.36) ALDH1A1MAPK1NPSR1
SCHEMBL18532099 0.79 ALDH1A1 (0.40) ALDH1A1L3MBTL1MAPK1NPSR1
SCHEMBL15693563 0.79 NOS3 (0.41) NOS3NOS2ADRB2ALDH1A1GAA
SCHEMBL2327508 0.78 NOS3 (0.59) NOS3NOS2ADRB2ALDH1A1GAA
SCHEMBL18415080 0.78 LOXL2 (0.34) ALDH1A1LOXL2LOXMAPK1RORC
SCHEMBL22903529 0.76 SMN1; SMN2 (0.38) ADRB2ALDH1A1L3MBTL1ARMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11655239-B2 Fused ring pyrimidine amino compound and preparation method, pharmaceutical composition, and use thereof Shanghai Institute of Material Medica, Chinese Academy of Sciences (CN) 2023-05-23 US disclosed
US-11242332-B2 Method for producing benzimidazole derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2022-02-08 US disclosed
US-20200347071-A1 AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2020-11-05 US disclosed
US-20200071295-A1 METHOD FOR PRODUCING BENZIMIDAZOLE DERIVATIVE Sumitomo Pharma Co., Ltd. (JP) 2020-03-05 US disclosed
US-20180094010-A1 TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE NEWGEN THERAPEUTICS INC (US) 2018-04-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200347071-A1 AMINOPYRROLOTRIAZINES AS KINASE INHIBITORS RIPK1, RIPK2, RIPK4 NOS3 1952/4885NOS2 1418/4885ADRB2 2899/4885
US-20180094010-A1 TRICYCLIC INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE PARP1, PARP2, PARP11 NOS3 3346/4885NOS2 3333/4885ADRB2 4547/4885
US-11242332-B2 Method for producing benzimidazole derivative CYP3A4, CYP3A5, CYP3A43 NOS3 1576/4885NOS2 1072/4885ADRB2 1562/4885
US-20200071295-A1 METHOD FOR PRODUCING BENZIMIDAZOLE DERIVATIVE CYP3A4, CYP3A5, CYP3A43 NOS3 1576/4885NOS2 1072/4885ADRB2 1562/4885
US-11655239-B2 Fused ring pyrimidine amino compound and preparation method, pharmaceutical composition, and use thereof DDR2, DDR1, DOCK2 NOS3 2362/4885NOS2 686/4885ADRB2 917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.